Futu news on December 30th$BOAN BIOTECH-B (06955.HK)$On the first day, it opened 0.51% higher at HK $19.9, with a pre-market turnover of HK $6.445 million.

In the previous trading day, Boan Bio-B opened 10.1% higher and closed down 1.11% at a loss of HK $44 per trade.

According to the previous public information, the number of applicants for the public placement of Boan Bio-B was 1875, the winning rate was 43.84%, and the subscription of 3 hands was stable. Futu Information collates the relevant data as follows:

Founded in 2013, the company is a comprehensive biopharmaceutical company dedicated to the development, manufacture and commercialization of quality biological products in different therapeutic areas in China and overseas. As of the latest practicable date, the company has three core products (i.e. BA6101, BA1102 and LY-CovMab) and eleven other drug products or drug candidates, including one product that has been commercialized in China (i.e. Boyonol ®(BA1101)); three drug candidates in phase III clinical trials in China; and seven other drug candidates at different stages of development. Two of these drug candidates, namely BA6101 and BA1102, are also conducting phase I clinical trials in the European Union.

In terms of financial position, as of 2021, the first half of 2021 and the first half of 2022, the company's income was 159 million yuan, 12 million yuan and 221 million yuan respectively, while the net loss for the same period was 225 million yuan, 128 million yuan and 153 million yuan respectively.